These findings suggested that the measurement of PCSK9 might be useful to predict the occurrence of MACEs in diabetic patients with CAD and high PCSK9 levels plus DM could enhance the prediction of worse clinical outcomes. The gene discussed is PCSK9; the disease is diabetes mellitus.